Evonik sells its US Jayhawk site supported by I-ADVISE

October 2018: Evonik is taking the next step in systematically focusing on specialty chemicals with the divestment of its US Jayhawk site in Galena, Kansas. The site produces precursors for agrochemicals, which are not included in the growth businesses defined by Evonik.
Jayhawk’s activities fall under the Agrochemicals & Polymer Additives business line in Evonik’s Performance Materials segment. Under a share deal, funds advised by the international investment firm Permira will acquire the site along with the company and its approximately 120 employees. The sale price is in the high double-digit million dollar range. The transaction is subject to approval by antitrust authorities in several countries.

I-ADVISE provided financial sell-side support to Evonik including the compilation of a financial fact book.

Permira is a global investment firm. Founded in 1985, the firm advises funds with a total committed capital of approximately €32 billion. The Permira funds have a long track record of successfully investing in industrial companies around the world and have invested over €4.6 billion in more than 20 companies. The CABB Group, headquartered in Sulzbach am Taunus, Germany, is a globally active producer of precursors, intermediates, and active substances for fine chemicals. With about 1,000 employees, the Group generates annual sales in the region of €450 million.

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.